Zymeworks Inc.

NasdaqGS ZYME

Zymeworks Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 68,863,010

Zymeworks Inc. Shares (Diluted, Weighted) is 68,863,010 for the year ending December 31, 2023, a 5.54% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Zymeworks Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 65,249,184, a 25.16% change year over year.
  • Zymeworks Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 52,131,596, a 3.47% change year over year.
  • Zymeworks Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 50,382,497, a 32.51% change year over year.
  • Zymeworks Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 38,022,014, a 30.71% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
NasdaqGS: ZYME

Zymeworks Inc.

CEO Mr. Kenneth H. Galbraith C.A.
IPO Date April 28, 2017
Location Canada
Headquarters 114 East 4th Avenue
Employees 294
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Similar companies

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

EDIT

Editas Medicine, Inc.

USD 1.14

-1.72%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

RLAY

Relay Therapeutics, Inc.

USD 4.35

-9.00%

AKRO

Akero Therapeutics, Inc.

USD 21.87

-3.36%

PTGX

Protagonist Therapeutics, Inc.

USD 36.67

-1.26%

ZNTL

Zentalis Pharmaceuticals, Inc.

USD 2.65

3.52%

ALEC

Alector, Inc.

USD 1.64

-8.38%

ANNX

Annexon, Inc.

USD 4.53

-8.30%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

CABA

Cabaletta Bio, Inc.

USD 2.19

1.39%

STOK

Stoke Therapeutics, Inc.

USD 8.68

-2.69%

MRSN

Mersana Therapeutics, Inc.

USD 0.63

2.01%

ARWR

Arrowhead Pharmaceuticals, Inc.

USD 18.05

-4.55%

PRQR

ProQR Therapeutics N.V.

USD 2.26

-0.44%

TVTX

Travere Therapeutics, Inc.

USD 17.07

-8.18%

CYTK

Cytokinetics, Incorporated

USD 45.23

-3.17%

YMAB

Y-mAbs Therapeutics, Inc.

USD 6.33

-2.61%

BLUE

bluebird bio, Inc.

USD 8.01

-5.65%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

StockViz Staff

January 15, 2025

Any question? Send us an email